RNA Interference for the Treatment of Papillomavirus Disease
Richa Singhania 1, §, Norliana Khairuddin 2, §, Daniel Clarke 3, §, Nigel AJ McMillan*, 3
1 The University of Queensland Diamantina Institute, Brisbane, Australia
2 Institute of Biological Sciences and Immunotherapeutics Laboratory, University of Malaya, Kuala Lumpur, Malaysia
3 School of Medical Science and Griffith Health Institute, Griffith University, Southport, Australia
Human Papillomavirus (HPV)-induced diseases are a significant burden on our healthcare system and current therapies are not curative. Vaccination provides significant prophylactic protection but effective therapeutic treatments will still be required. RNA interference (RNAi) has great promise in providing highly specific therapies for all HPV diseases yet this promise has not been realised. Here we review the research into RNAi therapy for HPV in vitro and in vivo and examine the various targets and outcomes. We discuss the idea of using RNAi with current treatments and address delivery of RNAi, the major issue holding back clinical adoption. Finally, we present our view of a potential path to the clinic.
Keywords: Clinical trial, delivery, human papillomavirus, RNA interference, siRNA, shRNA..
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
* Address correspondence to this author at the School of Medical Science
and Griffith Health Institute, Griffith University, Southport, Australia;
Tel: +61 7 55 52 71 35; Fax: + 61 7 55 52 89 08;
E-mail: email@example.com§Equal contributions